Barriers for HCV treatment in Italian Drug Abuse Service: Data from a multicentric observational study (SCUDO Project)

Titolo Rivista MISSION
Autori/Curatori Felice Nava, Alfio Lucchini, Marco Riglietta, Liborio Cammarata, Paola Fasciani, Giovanni Tavanti, Paola Trotta, Lucia Trevisi
Anno di pubblicazione 2020 Fascicolo 2020/54
Lingua Italiano Numero pagine 0 P. Dimensione file 0 KB
DOI 10.3280/mis54-2020oa10582
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Vedi l'articolo Scarica l'articolo open access

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

The epidemiological data suggests that people who use drugs (PWUDs) are the most important “reservoir” for the spread of HCV infection. For this reason PWUDs should be included in all HCV elimination plan as priority target for treatment.We performed an observational study in 5 Italian Drug Abuse Services (SerDs) with the main aims to determine: 1) the prevalence of HCV infection in PWUDs; 2) the most important barriers to HCV treatment.Of the about 4,000 drug users included in the study only about the 36% was tested and of them the 20% were anti HCV positive; only about the 60% of the HCV RNA positive patients were treated.The study showed several important barriers to the screening, especially when cannot used rapid tests and/or if test is not proposed periodically, and to the linkage to care, in particular when the HCV treatment cannot be given inside the SerDs.The study has also revealed as the harm reduction measures as suggested by WHO are not offered to all PWUDs. In conclusion the study suggests how inside the SerDs the barriers for HCV treatment that can be overcome with a simpler model of treatment as represented by the point of care.;

Keywords:HCV; PWUDs; Point of care; DAAs; Harm reduction

  1. AIFA criteria for HCV treatment (2019). Available from: www.aifa.gov.it/aggiornamento-epatite-c.
  2. Alimohsmmadi A., Holrksa J., Thiam A., Truong D., Conway B. (2018). Real-word efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting. Open Forum Infect Dis., 5/6: ofy120. DOI: 1.1093/ofid/ofy120.eCollection 2018 Jun
  3. Cunningham E.B., Applegate T.L., Lloyd A.R., Dore G.J., Grebely J. (2015). Mixed HCV infection and reinfection in people who inject drugs – impact on therapy. Nat. Rev. Gastroenterol Hepatol., 12(4): 218-230.
  4. Grebely J., Dore G.J. (2017). Treatment of HCV in persons who inject drugs: Treatment as prevention. Clin. Liver Dis., 9(4): 77-80.
  5. Grebely J., Dore G.J., Morin S., Rockstroh J.K., Klein M.B. (2017). Elimination of HCV as a public health concern among people who inject drugs by 2030 – what will it take to get there? Journal of the International AIDS Society, 20: 22146.
  6. Heimbach J.K. (2017). Overview of the updated ASSLSD guidelines for the management of HCC. Gastroenterol. Hepatol. (NY), 13(12): 751-753.
  7. Martin N.K., Vickerman P., Grebely J. et al. (2013). Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-actin antivirals. Hepathology, 58(5): 1598-1609.
  8. Nava F.A. (2019). I Ser.D. come presidi sul territorio: il ruolo dei Servizi nell’eliminazione di HCV. Quaderno di ReAdfiles, 20(Suppl. 2): 10-15.
  9. Nava F.A., Alberti A., Andreoni M., Babudieri S., Barbarini G., D’Egidio P.F., Leonardi C., Lucchini A. (2018a). For a program of eradication of hepatitis C in the population at risk (drug users and convicts). Acta Biomed., 89(Suppl. 10): 33-41.
  10. Nava F.A., Alberti A., Andreoni M., Babudieri S., Barbarini G., D’Egidio P.F., Leonardi C., Lucchini A. (2018b). Position paper. Per un programma di eliminazione dell’epatite C nella popolazione a rischio dei consumatori di sostanze e dei detenuti. Mission - Italian Quarterly Journal of Addiction, 49: 56-61.
  11. Nelson PK, Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. (2011). Global epidemiology of hepatitis B and hepathitis C in people who inject drugs: results of systematic review. Lancet, 378: 571-583.
  12. Relazione annuale al Parlamento sullo stato delle tossicodipendenze (2019). Availabe from: www.politicheantidroga.gov.it/it/dpa-in-sintesi/relazioniannuali-al-parlamento/relazione-annuale-al-parlamento-sul-fenomenodelle-tossicodipendenze-in-italia-anno-2019-dati-2018.
  13. Rossi C., Butt Z.A., Wong S., Buxton J.A., Islam N., Yu A., Darvishian M., Gilbert M., Wong J., Chapinal N., Binka M., Alvarez M., Tyndall M.W., Krajden M., Janjua N.Z., BC Hepatitis Testers Cohhort Team. J. Hepatol., 69(5): 1007-1014.
  14. Stroffolini T., D’Egidio P.F., Aceti A., Filippini P., Puoti M., Leonardi C., Almasio P.L., DAVIS drug Addictd, HCV prevalence in Italy and epidemiological observational, cross-sectional, multicenter study participating centers. J. Med. Vir, 84(10): 1608-1612.
  15. Taherkhani R., Farshadpour F. (2017). Global elimination of hepatitits C virus infection: progress and the remaining challenges. World J. Hepathol., 9(33): 1239-1252. DOI: 10.4254/wjh.v9.i33.1239
  16. Valencia La Rosa J,m Ryan P., Alvaro-Meca A., Troya J., Cuevas G., Gutiérrez J., Moreno S. (2018). HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: breaking barriers fo HCV elimination. PLoS One, 13(10): e0204795. DOI: 1.1371/journal.pone.0204795
  17. WHO (2017). Global Hepatitis Report 2017. Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. 2017. Available from: https://doi.org/10.1149)2.030203jes.

Felice Nava, Alfio Lucchini, Marco Riglietta, Liborio Cammarata, Paola Fasciani, Giovanni Tavanti, Paola Trotta, Lucia Trevisi, Barriers for HCV treatment in Italian Drug Abuse Service: Data from a multicentric observational study (SCUDO Project) in "MISSION" 54/2020, pp , DOI: 10.3280/mis54-2020oa10582